[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0111191B8 - moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos - Google Patents

moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos

Info

Publication number
BRPI0111191B8
BRPI0111191B8 BRPI0111191A BRPI0111191B8 BR PI0111191 B8 BRPI0111191 B8 BR PI0111191B8 BR PI0111191 A BRPI0111191 A BR PI0111191A BR PI0111191 B8 BRPI0111191 B8 BR PI0111191B8
Authority
BR
Brazil
Prior art keywords
mutant molecules
soluble ctla4
production
ctla4
molecules
Prior art date
Application number
Other languages
English (en)
Inventor
R Naemura Joseph
Bajorath Jurgen
S Linsley Peter
J Peach Robert
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0111191A publication Critical patent/BR0111191A/pt
Publication of BRPI0111191B1 publication Critical patent/BRPI0111191B1/pt
Publication of BRPI0111191B8 publication Critical patent/BRPI0111191B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

moléculas mutantes de ctla4 solúveis, método para sua produção e usos. a presente invenção fornece moléculas mutantes de ctla4 solúveis que ligam com maior afinidade ao antígeno cd80 e/ou cd86 do que ctla4 tipo selvagem ou ctla4ig não-mutada. as moléculas de ctla4 solúveis têm uma primeira seqüência de aminoácidos que compreende o domínio extracelular de ctla4, onde certos resíduos de aminoácido dentro da região s25r33 e da região m97-g1o7 são mutados. as moléculas mutantes da invenção podem também incluir segunda seqüência de aminoácidos que aumenta a solubilidade da molécula mutante.
BRPI0111191 2000-05-26 2001-05-23 moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos BRPI0111191B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (3)

Publication Number Publication Date
BR0111191A BR0111191A (pt) 2004-07-06
BRPI0111191B1 BRPI0111191B1 (pt) 2019-12-31
BRPI0111191B8 true BRPI0111191B8 (pt) 2021-05-25

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111191 BRPI0111191B8 (pt) 2000-05-26 2001-05-23 moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos

Country Status (41)

Country Link
EP (3) EP1536234B1 (pt)
JP (1) JP4328525B2 (pt)
KR (2) KR100889887B1 (pt)
CN (2) CN1309735C (pt)
AR (1) AR031699A1 (pt)
AT (1) ATE271066T1 (pt)
AU (2) AU2001263466C1 (pt)
BE (1) BE2011C041I2 (pt)
BR (1) BRPI0111191B8 (pt)
CA (1) CA2409748C (pt)
CY (2) CY2011019I1 (pt)
CZ (1) CZ304451B6 (pt)
DE (2) DE60104282T2 (pt)
DK (1) DK1248802T3 (pt)
EC (1) ECSP024365A (pt)
EE (2) EE05458B1 (pt)
EG (1) EG24459A (pt)
ES (2) ES2225549T3 (pt)
FR (1) FR11C0053I2 (pt)
GE (1) GEP20053658B (pt)
HK (2) HK1048126B (pt)
HU (2) HU228137B1 (pt)
IL (1) IL152315A (pt)
LT (1) LT5133B (pt)
LU (1) LU91902I2 (pt)
LV (1) LV12994B (pt)
MX (1) MXPA02011534A (pt)
MY (1) MY136113A (pt)
NO (2) NO330797B1 (pt)
PE (1) PE20011338A1 (pt)
PL (1) PL206267B1 (pt)
PT (1) PT1248802E (pt)
RU (1) RU2283847C2 (pt)
SI (1) SI1248802T1 (pt)
SK (1) SK288131B6 (pt)
TR (1) TR200402703T4 (pt)
TW (2) TWI319405B (pt)
UA (1) UA87432C2 (pt)
UY (1) UY26723A1 (pt)
WO (1) WO2001092337A2 (pt)
ZA (1) ZA200208944B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
DK1935427T3 (en) * 2000-07-03 2018-06-06 Bristol Myers Squibb Co APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
JP4837880B2 (ja) 2001-05-23 2011-12-14 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
KR20050088136A (ko) * 2002-12-23 2005-09-01 브리스톨-마이어스 스큅 컴퍼니 단백질 생산을 위한 포유류 세포 배양 방법
ATE488600T1 (de) * 2002-12-23 2010-12-15 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US10508144B2 (en) 2005-12-20 2019-12-17 Bristol-Myers Squibb Company Carbohydrate content of CTLA4 molecules
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
KR101378302B1 (ko) 2006-12-20 2014-03-28 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
EP2612867A1 (en) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
BRPI0920749A8 (pt) * 2008-10-02 2017-12-12 Emergent Product Dev Seattle Proteínas de ligação de antagonista multialvo cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN102822198B (zh) * 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
CN103534345A (zh) 2011-02-23 2014-01-22 安姆根有限公司 用于uvc暴射的细胞培养基及其相关方法
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
PL3207938T3 (pl) * 2012-05-11 2020-07-13 Medimmune Limited Warianty CTLA-4
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CA2877986A1 (en) 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
AU2014376225C1 (en) 2014-01-13 2019-02-21 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
ES2980493T3 (es) 2014-06-04 2024-10-01 Amgen Inc Métodos de recolección en cultivos de células de mamífero
CN107109455B (zh) 2014-12-01 2022-02-18 美国安进公司 用于操控糖蛋白的聚糖含量水平的方法
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
CN114773486A (zh) 2015-04-17 2022-07-22 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
KR20180073693A (ko) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
CN109715210B (zh) * 2016-09-19 2023-05-30 昂科医药 Cd80和cd86结合蛋白组合物及其用途
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
MX2019012567A (es) 2017-04-20 2020-02-13 Egenesis Inc Metodos para generar animales geneticamente modificados.
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
AU2020338947A1 (en) 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
PE20221788A1 (es) 2019-12-06 2022-11-25 Regeneron Pharma Composiciones de proteina anti-vegf y metodos para producir la misma
EP4146686A2 (en) 2020-05-08 2023-03-15 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
JP2023530712A (ja) 2020-06-18 2023-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 未処理ｃ末端リジンを正確に測定するための重ペプチドアプローチ
AU2021315939A1 (en) 2020-07-28 2023-02-23 Seagen Inc. Methods and systems for producing polypeptides
EP4448022A2 (en) 2021-12-16 2024-10-23 Bristol-Myers Squibb Company Detergent for viral inactivation
AU2023229164A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2123001T5 (es) 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
JP2003532370A (ja) * 1998-10-07 2003-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規なＴｈ２特異的分子およびその使用方法
DK1935427T3 (en) * 2000-07-03 2018-06-06 Bristol Myers Squibb Co APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES

Also Published As

Publication number Publication date
WO2001092337A3 (en) 2002-05-10
EP1536234A3 (en) 2009-06-03
DE122011100063I1 (de) 2012-06-14
WO2001092337A2 (en) 2001-12-06
JP2004511213A (ja) 2004-04-15
TR200402703T4 (tr) 2004-11-22
GEP20053658B (en) 2005-11-10
AU2001263466B2 (en) 2006-04-27
PL206267B1 (pl) 2010-07-30
CN1441810A (zh) 2003-09-10
CA2409748C (en) 2008-09-16
UY26723A1 (es) 2001-12-28
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
IL152315A (en) 2010-04-15
BE2011C041I2 (pt) 2020-08-20
HK1048126A1 (en) 2003-03-21
HUP0302201A2 (hu) 2003-10-28
RU2283847C2 (ru) 2006-09-20
EP1536234A2 (en) 2005-06-01
HUP0302201A3 (en) 2010-01-28
ES2225549T3 (es) 2005-03-16
NO2011027I2 (pt) 2011-12-15
CN101255192A (zh) 2008-09-03
NO20025656D0 (no) 2002-11-25
ECSP024365A (es) 2003-03-31
LV12994B (en) 2003-08-20
TW200906857A (en) 2009-02-16
KR100895134B1 (ko) 2009-05-04
CZ304451B6 (cs) 2014-05-14
PL366231A1 (en) 2005-01-24
BR0111191A (pt) 2004-07-06
PT1248802E (pt) 2004-11-30
HUS1300012I1 (hu) 2016-08-29
LT2002114A (en) 2003-12-29
EE05458B1 (et) 2011-08-15
EG24459A (en) 2009-07-16
PE20011338A1 (es) 2002-01-13
EP1248802B1 (en) 2004-07-14
CY2011019I1 (el) 2016-12-14
JP4328525B2 (ja) 2009-09-09
ATE271066T1 (de) 2004-07-15
DE60104282T2 (de) 2005-10-13
IL152315A0 (en) 2003-05-29
SI1248802T1 (en) 2005-02-28
LT5133B (lt) 2004-05-25
TWI319405B (en) 2010-01-11
HK1071931A1 (zh) 2005-08-05
SK15702002A3 (sk) 2004-01-08
FR11C0053I2 (fr) 2013-01-11
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
CA2409748A1 (en) 2001-12-06
AR031699A1 (es) 2003-10-01
SK288131B6 (sk) 2013-10-02
HU228137B1 (en) 2012-12-28
TWI314933B (en) 2009-09-21
BRPI0111191B1 (pt) 2019-12-31
EP3029062A1 (en) 2016-06-08
CY1117625T1 (el) 2017-04-26
MXPA02011534A (es) 2004-08-12
DE60104282D1 (de) 2004-08-19
NO2011027I1 (no) 2012-01-09
MY136113A (en) 2008-08-29
NO330797B1 (no) 2011-07-18
NO20025656L (no) 2002-11-25
CZ20023892A3 (cs) 2003-09-17
CN1309735C (zh) 2007-04-11
KR100889887B1 (ko) 2009-03-24
FR11C0053I1 (pt) 2012-01-13
HK1048126B (zh) 2005-03-04
EP1536234B1 (en) 2016-03-16
KR20030009502A (ko) 2003-01-29
EP1248802B9 (en) 2005-05-11
DK1248802T3 (da) 2004-11-15
AU2001263466C1 (en) 2006-10-26
ZA200208944B (en) 2004-02-13
ES2571852T3 (es) 2016-05-27
EE201100050A (et) 2011-10-17
EE200200659A (et) 2004-06-15
EE05557B1 (et) 2012-08-15
UA87432C2 (uk) 2009-07-27
AU6346601A (en) 2001-12-11

Similar Documents

Publication Publication Date Title
BRPI0111191B8 (pt) moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
AR036272A1 (es) Genes de metiltransferasas y usos de los mismos
Bierlmeier et al. Sortase‐Mediated Multi‐Fragment Assemblies by Ligation Site Switching
BR0015287A (pt) Moléculas recombinantes de fusão
AU2003287115A1 (en) Fluorescent proteins from copepoda species and methods for using same
BR112022026575A2 (pt) Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
MXPA04005992A (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.
Tran et al. Novel APC‐cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S
WO2002102852A3 (en) Modified cd8 molecule, nucleic acid encoding said molecule, and their therapeut ic use
AU4302000A (en) Genome sequence and polypeptides of pyrococcus (abissy), fragment and uses thereof
Law et al. OmpF enhances the ability of BtuB to protect susceptible Escherichia coli cells from colicin E9 cytotoxicity
Morgan et al. Structural and functional characterisation of two proteolytic fragments of the bacterial protein toxin, pneumolysin
Tatu et al. Role of a disulfide cross-link in the conformational stability of a thermostable xylanase
WO2023031943A3 (en) Cd28 shedding blocking agents
Kleinschmidt et al. Accelerated Publications Folding Intermediates of a β-Barrel Membrane Protein. Kinetic Evidence for a Multi-Step Membrane Insertion Mechanism
Váchová et al. Calcium as a regulator of Bacillus megaterium cytoplasmic proteolytic activity in vitro
Iseki et al. Purification and liposomal reconstitution of the oligopeptide transport activity in rat renal cortex using ceftibuten-affinity chromatography
WO2005040208A3 (en) Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
TR200401035T2 (tr) Arıtılmış proteinler, rekombinan DNA dizileri ve kahve bitkilerinin olgunlaşmasını kontrol etmek için işlemler

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2724 DE 21/03/2023 POR TER SIDO INDEVIDA.